Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

[1]  M. Diamond,et al.  ICAM-1 ( CD 54 ) : A Counter-Receptor for Mac-1 ( CDllb / CD 18 ) , 2002 .

[2]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[3]  E B Reilly,et al.  Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. , 2000, Journal of medicinal chemistry.

[4]  Miller,et al.  Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking , 2000, The Journal of investigative dermatology.

[5]  N. Hogg,et al.  From crystal clear ligand binding to designer I domains , 2000, Nature Structural Biology.

[6]  A. Mantovani,et al.  Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins , 2000, Laboratory Investigation.

[7]  J. R. Huth,et al.  NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Presta,et al.  EFFECTS OF HUMANIZED MONOCLONAL ANTIBODY TO RHESUS CD11a IN RHESUS MONKEY CARDIAC ALLOGRAFT RECIPIENTS12 , 2000 .

[9]  Richard W. Farndale,et al.  Structural Basis of Collagen Recognition by Integrin α2β1 , 2000, Cell.

[10]  V. Koteliansky,et al.  Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis , 2000 .

[11]  J. Dubernard,et al.  Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. , 2000, Transplantation proceedings.

[12]  P E Wright,et al.  NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. , 2000, Journal of molecular biology.

[13]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[14]  S. Harris,et al.  Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.

[15]  P. Reilly,et al.  Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. , 1999, Journal of immunology.

[16]  R. Kriwacki,et al.  Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. , 1999, Journal of molecular biology.

[17]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[18]  A. Issekutz.  Adhesion molecules mediating neutrophil migration to arthritis in vivo and across endothelium and connective tissue barriers in vitro , 1998, Inflammation Research.

[19]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Whitfield,et al.  Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. , 1998, Therapeutic drug monitoring.

[21]  E. Butcher,et al.  Chemokines and the arrest of lymphocytes rolling under flow conditions. , 1998, Science.

[22]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[23]  David A. Cheresh,et al.  Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications , 1997 .

[24]  D. Durand,et al.  A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. , 1996, Transplantation.

[25]  E. Nakakura,et al.  Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. , 1996, Transplantation.

[26]  Y. Shimada,et al.  Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. , 1996, Immunopharmacology.

[27]  E. Puré,et al.  Unresponsiveness to 2,4-dinitro-1-fluoro-benzene after treatment with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1 during sensitization. , 1996, Journal of immunology.

[28]  S. Katznelson,et al.  Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. , 1995, Kidney international. Supplement.

[29]  D. Leahy,et al.  Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[31]  Y. Takada,et al.  Critical Threonine and Aspartic Acid Residues within the I Domains of β2 Integrins for Interactions with Intercellular Adhesion Molecule 1 (ICAM-1) and C3bi (*) , 1995, The Journal of Biological Chemistry.

[32]  R. Liddington,et al.  Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18) , 1995, Cell.

[33]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[34]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[35]  J. Nickoloff,et al.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. , 1992, Analytical biochemistry.

[36]  P. Wright,et al.  Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy , 1991 .

[37]  A. Fischer,et al.  Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report. , 1991, Blood.

[38]  M. Diamond,et al.  ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18) , 1990, The Journal of cell biology.

[39]  K. Horgan,et al.  The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. , 1990, Journal of immunology.

[40]  D. E. Duggan,et al.  Physiological disposition of HMG-CoA-reductase inhibitors. , 1990, Drug metabolism reviews.

[41]  Michael L. Dustin,et al.  T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1 , 1989, Nature.